Merus Future Growth

Future criteria checks 2/6

Merus is forecast to grow earnings and revenue by 19.1% and 54.8% per annum respectively. EPS is expected to grow by 24.2% per annum. Return on equity is forecast to be -70.8% in 3 years.

Key information

19.1%

Earnings growth rate

24.2%

EPS growth rate

Biotechs earnings growth	28.3%
Revenue growth rate	54.8%
Future return on equity	-70.8%
Analyst coverage	Good
Last updated	20 Nov 2024

Recent future growth updates

Earnings Beat: Merus N.V. (NASDAQ:MRUS) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

May 12

Recent updates

Merus: Petosemtamab Set Up For December 2024 Data Presentation

Nov 05

We're Hopeful That Merus (NASDAQ:MRUS) Will Use Its Cash Wisely

Sep 20

Merus N.V.'s Innovative Cancer Therapies: Balancing Its IP Potential With Financial Risks

Aug 14

Analysts Just Made A Major Revision To Their Merus N.V. (NASDAQ:MRUS) Revenue Forecasts

Jun 01

Merus Stock: Priced High After An ASCO Surprise Surge (Maintain Buy)

May 24

Earnings Beat: Merus N.V. (NASDAQ:MRUS) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

May 12

Risks To Shareholder Returns Are Elevated At These Prices For Merus N.V. (NASDAQ:MRUS)

Dec 18

We Think Merus (NASDAQ:MRUS) Needs To Drive Business Growth Carefully

Sep 19

Merus N.V.'s (NASDAQ:MRUS) Business Is Yet to Catch Up With Its Share Price

Jun 20

Is Merus (NASDAQ:MRUS) In A Good Position To Invest In Growth?

May 24

Merus N.V. (NASDAQ:MRUS) Shares Could Be 26% Below Their Intrinsic Value Estimate

Feb 08

Merus GAAP EPS of -$0.13 beats by $0.49, revenue of $12.68M beats by $2.23M

Aug 08

Merus N.V. initiated with Buy at Stifel based on three bispecific antibodies

Aug 02

Merus: Precision Oncology Pioneer Continues To Execute In The Clinic

Jun 30

Need To Know: Analysts Are Much More Bullish On Merus N.V. (NASDAQ:MRUS)

May 14

Merus (NASDAQ:MRUS) Is In A Strong Position To Grow Its Business

Apr 25

New Forecasts: Here's What Analysts Think The Future Holds For Merus N.V. (NASDAQ:MRUS)

Mar 03

We're Not Worried About Merus' (NASDAQ:MRUS) Cash Burn

Nov 25

News Flash: Analysts Just Made A Sizeable Upgrade To Their Merus N.V. (NASDAQ:MRUS) Forecasts

Aug 08

Calculating The Intrinsic Value Of Merus N.V. (NASDAQ:MRUS)

Jul 28

We're Not Very Worried About Merus' (NASDAQ:MRUS) Cash Burn Rate

Jul 02

Earnings and Revenue Growth Forecasts

NasdaqGM:MRUS - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	84	-274	-272	-232	14
12/31/2025	54	-271	-257	-215	16
12/31/2024	36	-248	-219	-190	15
9/30/2024	36	-245	-157	-156	N/A
6/30/2024	35	-168	-104	-103	N/A
3/31/2024	38	-150	-150	-150	N/A
12/31/2023	44	-155	-146	-142	N/A
9/30/2023	46	-177	-142	-136	N/A
6/30/2023	41	-178	-159	-150	N/A
3/31/2023	43	-152	-151	-140	N/A
12/31/2022	42	-131	-158	-150	N/A
9/30/2022	46	-64	-157	-151	N/A
6/30/2022	53	-54	-137	-133	N/A
3/31/2022	52	-76	-126	-125	N/A
12/31/2021	49	-67	-60	-60	N/A
9/30/2021	43	-80	-53	-52	N/A
6/30/2021	38	-89	-42	-41	N/A
3/31/2021	32	-79	-37	-35	N/A
12/31/2020	30	-86	-81	-80	N/A
9/30/2020	29	-83	-76	-75	N/A
6/30/2020	28	-69	-80	-78	N/A
3/31/2020	29	-65	-77	-75	N/A
12/31/2019	31	-55	-66	-63	N/A
9/30/2019	37	-32	-61	-56	N/A
6/30/2019	35	-34	-63	-58	N/A
3/31/2019	36	-26	-50	-45	N/A
12/31/2018	38	-28	-50	-46	N/A
9/30/2018	34	-41	-48	-46	N/A
6/30/2018	33	-45	N/A	-43	N/A
3/31/2018	34	-66	N/A	-54	N/A
12/31/2017	26	-78	N/A	-45	N/A
9/30/2017	18	-100	N/A	-44	N/A
6/30/2017	12	-87	N/A	-33	N/A
3/31/2017	6	-66	N/A	-27	N/A
12/31/2016	3	-50	N/A	-27	N/A
9/30/2016	4	-25	N/A	-27	N/A
6/30/2016	3	-26	N/A	-30	N/A
3/31/2016	3	-27	N/A	-29	N/A
12/31/2015	2	-25	N/A	-25	N/A
9/30/2015	2	-25	N/A	-23	N/A
6/30/2015	2	-23	N/A	-19	N/A
3/31/2015	1	-20	N/A	-17	N/A
12/31/2014	2	-21	N/A	-18	N/A
12/31/2013	1	-14	N/A	-10	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: MRUS is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: MRUS is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: MRUS is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: MRUS's revenue (54.8% per year) is forecast to grow faster than the US market (8.9% per year).

High Growth Revenue: MRUS's revenue (54.8% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: MRUS is forecast to be unprofitable in 3 years.

Merus Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Price target increased by 21% to US$73.36

Consensus revenue estimates increase by 26%

Earnings Beat: Merus N.V. (NASDAQ:MRUS) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Price target increased by 7.6% to US$59.18

Price target increased by 16% to US$51.60

Consensus EPS estimates upgraded to US$2.60 loss

Recent updates

Merus: Petosemtamab Set Up For December 2024 Data Presentation

Merus N.V. Announces First Patient Dosed in Liger-Hn1, A Phase 3 Trial Evaluating Petosemtamab in Combination with Pembrolizumab in 1L R/M HNSCC

We're Hopeful That Merus (NASDAQ:MRUS) Will Use Its Cash Wisely

Merus N.V.'s Innovative Cancer Therapies: Balancing Its IP Potential With Financial Risks

Merus N.V. Announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 2L CRC

Merus N.V. Announces Chief Medical Officer Changes

Merus N.V. Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab At the 2024 ASCO® Annual Meeting

Analysts Just Made A Major Revision To Their Merus N.V. (NASDAQ:MRUS) Revenue Forecasts

Merus N.V. has completed a Follow-on Equity Offering in the amount of $400.15 million.

Merus N.V. has filed a Follow-on Equity Offering in the amount of $300 million.

Price target increased by 21% to US$73.36

Merus Stock: Priced High After An ASCO Surprise Surge (Maintain Buy)

Consensus revenue estimates increase by 26%

Merus N.V. Announces Petosemtamab Grants Breakthrough Therapy Designation by the U.S. FDA

Earnings Beat: Merus N.V. (NASDAQ:MRUS) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Merus (NASDAQ:MRUS) Is In A Good Position To Deliver On Growth Plans

First quarter 2024 earnings released: US$0.59 loss per share (vs US$0.86 loss in 1Q 2023)

Merus N.V. Appoints Jason Haddock as Non-Executive Director

Merus N.V., Annual General Meeting, May 07, 2024

Price target increased by 7.6% to US$59.18

Merus N.V. announced that it has received $25.000035 million in funding from Gilead Sciences, Inc.

Full year 2023 earnings: EPS and revenues miss analyst expectations

Merus: Positive Zenocutuzumab Data In 2024 Could Provide BLA Advancement

Price target increased by 16% to US$51.60

Merus N.V. has filed a Follow-on Equity Offering in the amount of $300 million.

Merus N.V.'s (NASDAQ:MRUS) Shares Climb 30% But Its Business Is Yet to Catch Up

Merus Stock: Rally Seems Overdone

Are Investors Undervaluing Merus N.V. (NASDAQ:MRUS) By 45%?

Risks To Shareholder Returns Are Elevated At These Prices For Merus N.V. (NASDAQ:MRUS)

EVP, Company Secretary notifies of intention to sell stock

Consensus EPS estimates upgraded to US$2.60 loss

Consensus estimates of losses per share improve by 12%

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Merus N.V. Announces Interim Data Continues to Demonstrate Robust and Durable Responses in NRG1+ Cancer

New major risk - Revenue and earnings growth

We Think Merus (NASDAQ:MRUS) Needs To Drive Business Growth Carefully

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

U.S. Food and Drug Administration Grants Second Breakthrough Therapy Designation for zenocutuzumab (Zeno) of Merus N.V

Merus N.V.'s (NASDAQ:MRUS) Business Is Yet to Catch Up With Its Share Price

Merus Appoints Greg Perry as Chief Financial Officer

Is Merus (NASDAQ:MRUS) In A Good Position To Invest In Growth?

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates upgraded to US$3.63 loss

Independent Non Executive Director exercised options to buy US$1.5m worth of stock.

Price target increased by 8.6% to US$40.67

Price target increased by 8.5% to US$39.67

Chief Business Officer exercised options to buy US$1.9m worth of stock.

Full year 2022 earnings released: US$2.92 loss per share (vs US$1.73 loss in FY 2021)

Now 21% undervalued

Merus N.V. (NASDAQ:MRUS) Shares Could Be 26% Below Their Intrinsic Value Estimate

Merus N.V. Announces Executive Changes

Price target decreased to US$37.11

Consensus forecasts updated

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to US$38.44

Merus N.V. Presents First in Human Data on MCLA-129 at the 34th EORTC/NCI/AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics

Consensus forecasts updated

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Merus GAAP EPS of -$0.13 beats by $0.49, revenue of $12.68M beats by $2.23M

Merus N.V. initiated with Buy at Stifel based on three bispecific antibodies

Merus: Precision Oncology Pioneer Continues To Execute In The Clinic

Merus N.V. Presents Clinical Data on Zenocutuzumab in NRG1-Fusion Cancer at the 2022 American Society of Clinical Oncology Annual Meeting

Consensus revenue estimates increase by 15%

Need To Know: Analysts Are Much More Bullish On Merus N.V. (NASDAQ:MRUS)

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Merus N.V., Annual General Meeting, May 31, 2022

Merus (NASDAQ:MRUS) Is In A Strong Position To Grow Its Business

Executive VP exercised options and sold US$947k worth of stock

Merus N.V. Announces Publication of Abstract on MCLA-129 At the American Association for Cancer Research 2022 Annual Meeting